NeuroPace, Inc. (NPCE)
| Market Cap | 274.58M -36.3% |
| Revenue (ttm) | 106.75M +29.2% |
| Net Income | -18.92M |
| EPS | -0.56 |
| Shares Out | 34.45M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,768,549 |
| Open | 7.49 |
| Previous Close | 7.56 |
| Day's Range | 7.05 - 8.18 |
| 52-Week Range | 5.46 - 19.60 |
| Beta | 1.93 |
| Analysts | Buy |
| Price Target | 12.22 (+53.33%) |
| Earnings Date | Nov 12, 2026 |
About NPCE
NeuroPace, Inc. operates as a medical device company in the United States. The company develops RNS system, a brain-responsive neuromodulation system that delivers personalized, real-time treatment at the seizure source for treating drug-resistant focal epilepsy. Its RNS System includes RNS neurostimulator, cortical strip and depth leads, and Patient Remote Monitor, as well as other implantable and non-implantable accessories. In addition, the company provides physician tablet which is used for prescribing and managing clinicians for programmin... [Read more]
Financial Performance
In 2025, NeuroPace's revenue was $99.99 million, an increase of 25.13% compared to the previous year's $79.91 million. Losses were -$21.47 million, -20.91% less than in 2024.
Financial StatementsAnalyst Summary
According to 10 analysts, the average rating for NPCE stock is "Buy." The 12-month stock price target is $12.22, which is an increase of 53.33% from the latest price.
News
NeuroPace price target lowered to $12 from $22 at Mizuho
Mizuho analyst Anthony Petrone lowered the firm’s price target on NeuroPace (NPCE) to $12 from $22 and keeps an Outperform rating on the shares following the Q3 report. The company…
NeuroPace price target lowered to $12 from $20 at H.C. Wainwright
H.C. Wainwright lowered the firm’s price target on NeuroPace (NPCE) to $12 from $20 and keeps a Buy rating on the shares. The company reported a sales miss in Q3…
Leerink downgrades NeuroPace amid commercial setbacks, cuts to growth outlook
As previously reported, Leerink downgraded NeuroPace (NPCE) to Market Perform from Outperform with a price target of $7, down from $20, following the company’s commercial setbacks in Q3. The firm…
NeuroPace price target lowered to $13 from $20 at Lake Street
Lake Street lowered the firm’s price target on NeuroPace (NPCE) to $13 from $20 and keeps a Buy rating on the shares. The firm would be buyers on post-earnings weakness…
NeuroPace downgraded to Equal Weight from Overweight at Wells Fargo
Wells Fargo downgraded NeuroPace (NPCE) to Equal Weight from Overweight with a price target of $9, down from $19. The Q3 miss extends beyond one quarter, says the analyst, who…
NeuroPace price target lowered to $14 from $18 at KeyBanc
KeyBanc lowered the firm’s price target on NeuroPace (NPCE) to $14 from $18 on lower estimates, while keeping an Overweight rating on the shares. Q3 represented a material setback to…
NeuroPace downgraded to Neutral from Overweight at JPMorgan
JPMorgan downgraded NeuroPace (NPCE) to Neutral from Overweight with a price target of $9, down from $20. Neuropace reported a “disappointing” Q3 with guidance moving lower and while there are…
NeuroPace downgraded to Market Perform from Outperform at Leerink
Leerink downgraded NeuroPace (NPCE) to Market Perform from Outperform with a $7 price target
NeuroPace reports Q3 EPS (10c), consensus (9c)
Reports Q3 revenue $23.1M, consensus $27.2M. “Third-quarter revenue was below our expectations, and we have taken and are taking action to improve commercial execution and return the business to histo...
NeuroPace cuts FY26 revenue view to $91M-$92M from $99.5M-$101.5M
Consensus $100.4M.
NeuroPace Earnings Call Transcript: Q3 2026
Q3 revenue declined 1.1% YoY as account disruptions, sales transitions and the SEEG exit weighed on procedures. FY26 guidance was cut, while recovery, commercial investment and potential IGE, adolescent and Remote Care approvals underpin the growth outlook.
NeuroPace Earnings release: Q3 2026
NeuroPace released its Q3 2026 earnings on November 12, 2026, summarizing the period's financial results.
NeuroPace Quarterly report: Q3 2026
NeuroPace has published its Q3 2026 quarterly earnings report on November 12, 2026.
NeuroPace Slides: Q3 2026
NeuroPace has posted slides in relation to its Q3 2026 quarterly earnings report, which was published on November 12, 2026.
NeuroPace Reports Third Quarter 2026 Financial Results and Provides Revised Full Year Guidance
MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--NeuroPace, Inc. (Nasdaq: NPCE), a medical device company focused on transforming the lives of people living with epilepsy, today reported financial results for ...
NeuroPace to Report Third Quarter 2026 Financial Results on November 12, 2026
MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--NeuroPace, Inc. (Nasdaq: NPCE), a medical device company focused on transforming the lives of people living with epilepsy, today announced it will report financ...
NeuroPace initiated with an Overweight at KeyBanc
KeyBanc analyst Brett Fishbin last night initiated coverage of NeuroPace (NPCE) with an Overweight rating and $18 price target The company is “effectively commercializing a differentiated approach” to...
NeuroPace initiated with an Overweight at KeyBanc
KeyBanc initiated coverage of NeuroPace (NPCE) with an Overweight rating and $18 price target
NeuroPace Transcript: 12th Annual Cantor Fitzgerald Global Healthcare Conference
Strong core growth continues with a 21% revenue increase and robust patient pipeline. FDA approval for IGE could expand the addressable market by 20%, with compelling clinical data supporting broad adoption. AI-driven tools and remote monitoring aim to reduce friction and support scalable growth.
NeuroPace Transcript: Wells Fargo 21st Annual Healthcare Conference
Drug-resistant epilepsy remains under-penetrated, with new initiatives and expanded indications like IGE expected to drive adoption. The RNS system's clinical data and AI tools position it for growth, with FDA approval for IGE potentially in 2027 and a ramp-up in commercialization to follow.
NeuroPace to Participate in 2026 Cantor Global Healthcare Conference
MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--NeuroPace, Inc. (Nasdaq: NPCE), a medical device company focused on transforming the lives of people living with epilepsy, today announced that its management t...
NeuroPace to Participate in Wells Fargo 21st Annual Healthcare Conference
MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--NeuroPace, Inc. (Nasdaq: NPCE), a medical device company focused on transforming the lives of people living with epilepsy, today announced that its management t...
NeuroPace Earnings Call Transcript: Q2 2026
Q2 revenue grew 17% to $22.8M, with RNS System revenue up 21% year-over-year and record highs in prescribers and patient pipeline. Guidance for 2026 was raised, reflecting strong core business momentum, while the IGE regulatory process continues with optimism for approval.
NeuroPace Earnings release: Q2 2026
NeuroPace released its Q2 2026 earnings on August 11, 2026, summarizing the period's financial results.
NeuroPace Quarterly report: Q2 2026
NeuroPace has published its Q2 2026 quarterly earnings report on August 11, 2026.